Activaero has entered into research collaboration with Italian pharmaceutical firm Chiesi Farmaceutici to develop an effective solution to treat patients with cystic fibrosis (CF). Under the deal, Activaero will offer its flow and volume ...
c (tobramycin inhalation powder) 28mg per capsule has obtained FDA approval for the treatment of bacterial lung infection in certain cystic fibrosis (CF) patients. TOBI Podhaler is new non-nebulized formulation and delivery system of ...
The sharemarket broke a 10-day winning streak yesterday after the US Federal Reserve said the country's economy had paused recently. However, the Australian bond market found support after a wave of selling. "Being the last day of the ...
Tags: stocks, US economy, sharemarket
Celerion has added a bronchoscopy suite in the Belfast, Northern Ireland, UK facility, to expand its respiratory capabilities. The company can perform bronchoalveolar lavage (BAL) using study participants from its database. The ...
The Anti-Infective Drugs Advisory Committee (AIDAC) to the US Food and Drug Administration (FDA) has recommended the use of Novartis's tobramycin inhalation powder (TIP) to treat cystic fibrosis (CF) patients whose lungs contain bacteria ...
US-based Cornerstone Therapeutics has entered into an agreement to acquire the US marketing rights to Chiesi Farmaceutici's BETHKIS (Tobramycin Inhalation Solution), designed for the treatment of cystic fibrosis patients with Pseudomonas ...
Tags: US-based Cornerstone Therapeutics, Chiesi Farmaceutici's BETHKIS